A Study to Evaluate Relative Bioavailability Proton Pump Inhibitor (PPI) (Rabeprazole) Effect Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

  • STATUS
    Recruiting
  • days left to enroll
    18
  • participants needed
    42
  • sponsor
    AstraZeneca
Updated on 18 November 2020

Summary

This study will be a 2-part, open-label, single-center relative bioavailability, PPI effect, food-effect and particle size effect randomized crossover study of acalabrutinib tablets in healthy subjects (males or females). The study will be divided in 2 study parts; following a review of the safety and Pharmacokinetics (PK) data from Part 1, the study is planned to be continued with Part 2.

Description

The study will be divided in 2 study parts; Part 1 of this study will be an open-label, 3-treatment-period, 4-treatment, single-center relative bioavailability, PPI effect, and food-effect randomized crossover study of a new acalabrutinib tablet in healthy subjects (males or females).

The relative bioavailability part of Study Part 1 is designed to investigate the PK of the acalabrutinib tablet compared with the PK of acalabrutinib capsule, when administered as a single dose with water under the fasted condition (>10 hours). The PPI effect part of Study Part 1 is designed to compare the PK of acalabrutinib tablet with or without coadministration of the PPI rabeprazole. The food-effect part of Study Part 1 is designed to compare the PK of acalabrutinib tablet under fed and fasted conditions. For each subject, a SmartPill will be administered with 120 mL of still water followed immediately by a single oral dose of acalabrutinib tablet (Treatment B, C or D) or acalabrutinib capsule (Treatment A) administered with 120 mL of still water.

Study Part 1 will comprise:

  • A screening period of maximum 28 days;
  • Three treatment periods during which subjects will be resident from prior to the evening meal the night before dosing with Investigational medicinal product (IMP) (Day -1) until at least 48 hours after dosing; discharged on the morning of Day 3; and
  • A Follow-up Visit within 7 to 10 days. There will be a minimum washout period of at least 7 days between each acalabrutinib administration.

A decision to continue with Study Part 2 will be made following a review of the preliminary data for relative bioavailability (acalabrutinib tablet versus acalabrutinib capsule), food effect, PPI effect, and safety observed in Part 1.

Part 2 of this study will be an open-label, 4-treatment-period, 4-treatment, single-center relative bioavailability, randomized crossover study to determine the effect of particle size on the PK of a single dose of acalabrutinib tablet in healthy subjects (males or females).

This relative bioavailability study is designed to investigate the PK of acalabrutinib tablets with various drug substance particle size distributions and the PK of acalabrutinib solution at a single oral dose of 100 mg under the fasted condition (>10 hours).

Study Part 2 will comprise:

  • A screening period of maximum 28 days;
  • Four treatment periods during which subjects will be resident prior to the evening meal the night before dosing with IMP (Day -1) until at least 48 hours after dosing; discharged on the morning of Day 3; and
  • A Follow-up Visit within 7 to 10 days. There will be a minimum washout period of at least 3 days between each acalabrutinib administration.

Details
Treatment Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1, Treatment D- Part 1, Treatment A-Part 2, Treatment B - Part 2, Treatment C - Part 2, Treatment D - Part 2
Clinical Study IdentifierNCT04488016
SponsorAstraZeneca
Last Modified on18 November 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 55 yrs?
Gender: Male or Female
Do you have any of these conditions: B-cell Lymphoid Cancer or Bioavailability?
Provision of signed and dated, written informed consent prior to any study specific procedures
Healthy adult male or female subjects aged 18 - 55 years with suitable veins for cannulation or repeated venipuncture
Male subject must adhere to the contraception methods
Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating and must be of non-childbearing potential, confirmed at screening
Have a Body mass index (BMI) between 18.5 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive at screening
Understands the study procedures in the Informed Consent Form (ICF) and willing and able to comply with the protocol
Willingness and ability to swallow study drugs, including the SmartPill
Willingness to consume a standardized, high- calorie, high-fat FDA breakfast

Exclusion Criteria

History of any clinically significant disease or disorder which, in the opinion of the Principal Investigator (PI), may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study
History or presence of gastrointestinal (GI), hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
Evidence of ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections)
Any clinically significant illness, medical/surgical procedure, or trauma within 30 days of the first administration of IMP
Any clinically significant abnormalities in clinical chemistry, hematology, coagulation, or urinalysis results, at screening and first admission to the study unit (first treatment period) as judged by the PI, and defined as: (1) Serum Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), alkaline phosphatase (ALP), and serum bilirubin (total and direct)
> Upper limit of normal (ULN). (2) Hemoglobin < ULN
\. Any clinically significant abnormal findings in vital signs at screening
and first admission to the study unit (first treatment period), as judged by
the PI
\. Any clinically significant abnormalities on 12-lead ECG at screening and
first admission to the study unit (first treatment period), as judged by the
PI
\. Any positive result on screening for serum hepatitis B surface antigen
hepatitis B core antibody (anti-HBc), hepatitis C antibody, and HIV antibody
\. Known or suspected history of drug abuse, as judged by the PI
\. Has received another new chemical entity (defined as a compound which has
not been approved for marketing) within 90 days of the first administration of
IMP in this study
The period of exclusion begins 90 days after the final dose or 30 days after
the last visitwhichever is the longest
\. Plasma donation within 30 days of screening or any blood donation/loss
more than 500 mL during the 90 days prior to screening
\. History of severe allergy/hypersensitivity or ongoing
allergy/hypersensitivity, as judged by the PI or history of hypersensitivity
to drugs with a similar chemical structure or class to acalabrutinib or
rabeprazole
\. Current smokers or those who have smoked or used nicotine products
(including e-cigarettes) within the 90 days prior to screening
\. Positive screen for drugs of abuse or cotinine at screening or on each
admission to the study center or positive screen for alcohol on each admission
to the study center
\. Use of drugs with enzyme-inducing properties such as St John's Wort
within 3 weeks prior to the first administration of IMP
\. Use of any prescribed or non-prescribed medication including antacids
analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose
vitamins (intake of 20 to 600 times the recommended daily dose) and minerals
during the 2 weeks prior to the first administration of IMP or longer if the
medication has a long half-life. Hormone replacement therapy will not be
allowed
\. Known or suspected history of alcohol or drug abuse or excessive intake
of alcohol as judged by the PI
\. Excessive intake of caffeine-containing drinks or food (e.g., coffee
tea, chocolate) as judged by the PI. Excessive intake of caffeine defined as
the regular consumption of more than 600 mg of caffeine per day (e.g., >5 cups
of coffee) or would likely be unable to refrain from the use of caffeine-
containing beverages during confinement at the investigational site
\. Part 1 only: Inability or unwillingness to swallow SmartPill, including
Subject has any of the following contraindications for the SmartPill
A history of gastric bezoars
Swallowing disorders
Suspected or known strictures, fistulas or physiological/mechanical GI obstruction
History of GI surgery within 90 days of administration
Severe dysphagia to food or pills
Crohn's disease or diverticulitis
Cardiac pacemakers or other implanted electromedical devices 20 Involvement of any AstraZeneca, Acerta Pharma, Parexel or study site employee or their close relatives. 21 Subjects who have previously received acalabrutinib. 22 Judgment by the PI that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements. 23 Subjects who cannot communicate reliably with the Investigator. 24 Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet